[{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"MAR001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Marea Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"","sponsorNew":"Marea Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Marea Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"ANGPTL4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"MAR002","moa":"GHR","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"5","companyTruncated":"Marea Therapeutics \/ ProBioGen"}]

Find Clinical Drug Pipeline Developments & Deals by Marea Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The parternship aims to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly.

                          Product Name : MAR002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 05, 2025

                          Lead Product(s) : MAR002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : ProBioGen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : MAR001 is a potential first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. It is being evaluated for the treatment of hypertriglyceridemia.

                          Product Name : MAR001

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : MAR001

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The financing aims to fund the company’s lead product, MAR001, a monoclonal antibody targets ANGPTL4. Currently, it is being evaluated in early-stage trials for the treatment of hypertriglyceridemia.

                          Product Name : MAR001

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 18, 2024

                          Lead Product(s) : MAR001

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sofinnova Investments

                          Deal Size : $190.0 million

                          Deal Type : Series B Financing

                          blank